Musculoskeletal | Preclinical Developments

Arrowhead Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Arrowhead and Horizon Collaborate to Develop RNAi Therapeutic

Lead Product(s): ARO-XDH

Therapeutic Area: Musculoskeletal Product Name: ARO-XDH

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Horizon Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 21, 2021

Details:

Arrowhead will conduct all activities through preclinical stages of development of the siRNA therapeutic, ARO-XDH. Horizon will receive a worldwide exclusive license to ARO-XDH and will be wholly responsible for clinical development and commercialization.

Amplicore

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round

Lead Product(s): AM3101

Therapeutic Area: Musculoskeletal Product Name: AM3101

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Photon Fund

Deal Size: $4.0 million Upfront Cash: Undisclosed

Deal Type: Financing March 25, 2021

Details:

The proceeds from the financing will enable Amplicore to complete the preclinical development of its two leading products, AM3101 and AM1101, and position the company for the next round of financing.